. In humans, titin is encoded by a single gene 11 (TTN) comprising 364 exons that undergo extensive differential splicing, particularly in the I-band, across tissues and during development and disease (FIG. 1b,c) . In the heart, titin isoforms can be grouped into at least four families: long and short isoforms that span the sarcomere (known as N2BA, >300 exons; and N2B, ~190 exons), ultra-long fetal isoforms that similarly span the sarcomere, and very short isoforms that do not span the sarcomere. The N2BA, N2B, and fetal sarcomere-spanning forms have the same terminal sequences, but differ in the content of the I-band spring elements, which are spliced out of the shorter form as symmetric cassettes 9 , maintaining the reading frame of the protein. Considerable additional variability exists in the precise exon composition of individ ual titin molecules, which is not well characterized. For convenience, these isoforms can be succinctly represented by four distinct molecules: a short, stiff form that predominates in the adult left ventricle 12, 13 ; a long, compliant form that is upregulated in heart failure syndromes, including dilated cardiomyopathy (DCM) [13] [14] [15] [16] ; even longer forms expressed during fetal development 17 ; and a much shorter 46-exon isoform, often referred to as the Novex-3 isoform 11 , which shares the N-terminal sequence, but has an alternative C-terminal exon, and does not span the sarcomere. The physiological role of the Novex-3 isoform is unclear. In the past 2 years, several alternative N-terminal start sites have been identified 18, 19 , although their relevance and roles are not fully understood.
DCM is defined by left ventricular (LV) or biventricular systolic dysfunction and dilatation not explained by abnormal loading conditions or coronary disease 20 and affects approximately 1 in 250 individuals 21 . Causes of DCM can be classified as being genetic or nongenetic 22 , with titin-truncating variants (TTNtv) being the most prevalent genetic cause 23 , and nongenetic causes including drugs and toxins (most commonly alcohol or chemotherapy), myocarditis, and pregnancy 20 , although it is increasingly recognized that a genetic predisposition can also interact with extrinsic or environmental factors 24 . [1] [2] [3] Abstract | Dilated cardiomyopathy (DCM) affects approximately 1 in 250 individuals and is the leading indication for heart transplantation. DCM is often familial, and the most common genetic predisposition is a truncating variation in the giant sarcomeric protein, titin, which occurs in up to 15% of ambulant patients with DCM and 25% of end-stage or familial cases. In this article, we review the evidence for the role of titin truncation in the pathogenesis of DCM and our understanding of the molecular mechanisms and pathophysiological consequences of variation in the gene encoding titin (TTN). Such variation is common in the general population (up to 1% of individuals), and we consider key features that discriminate variants with disease-causing potential from those that are benign. We summarize strategies for clinical interpretation of genetic variants for use in the diagnosis of patients and the evaluation of their relatives. Finally, we consider the contemporary and potential future role for genetic stratification in cardiomyopathy and in the general population, evaluating titin variation as a predictor of outcome and treatment response for precision medicine.
Despite improvements in pharmacological and devicebased therapy, clinical outcomes remain poor, with a mortality of 20% at 5 years 25, 26 , and with DCM being the leading cause of heart transplantation 27, 28 .
In this Review, we discuss the current understanding of cardiomyopathy associated with alterations in titin, with a broad overview of the gene, the effect of variants in TTN and their clinical interpretation, the molecular and physiological consequences of pathogenic TTNtv, and the future application of genetic stratification for precision medicine in patients with DCM.
Titin in heart disease
Titin was first implicated in human genetic disease in 1998, when linkage analysis mapped a tibial muscular dystrophy locus to chromosome 2q31 (REF. 29 ). The following year, an autosomal dominant DCM was also mapped to 2q31 (REF. 30 ). In each study, the locus was noted to contain TTN, which was highlighted as a strong candidate gene, but in neither study was TTN demonstrated conclusively to be the cause of the disease. In 2002, titin variants were confirmed to cause DCM by the demonstration of linkage of distinct TTN mutations in two unrelated pedigrees 31 . In a related article in the same issue of Nature Genetics, researchers described a TTN-mutant zebrafish with a DCM-like phenotype 32 . Titin was, therefore, shown to be causative in some cases of DCM in isolated families, but its overall contribution to inherited cardiomyopathy remained unknown. Comprehensive DNA sequencing of TTN was impractical with the technology of the time, given the size of the gene. In subsequent years, additional isolated families with TTN variants causing typical adult-onset DCM 33 , and an early-onset recessive disease characterized by both skeletal and cardiac myopathy 34 were identified by linkage analysis. However, not until a decade later in 2012 was the importance of titin as a major cardiac disease gene fully appreciated. High-throughput DNA sequencing technology, newly available at that time, allowed comprehensive analysis of TTN in substantial cohorts of patients with end-stage or familial DCM (n = 312) or hypertrophic cardio myopathy (HCM; n = 231) as well as in healthy control individuals (n = 249) 23 . TTNtv (vari ants predicted to yield a truncated protein if transcribed and translated, including nonsense variants, frameshift insertions and deletions, and canonical splice-disrupting variants) were found in up to 27% of patients with DCM and were significantly enriched in patients with DCM compared with healthy controls (3%; P = 9 × 10 −14 ) or patients with HCM (1%; P = 3 × 10 −16 ), and variants co-segregated with DCM in families (combined logar ithm of the odds (LOD) score 11.1), revealing TTNtv as the largest-known genetic contribution to DCM 23 . The association between DCM and TTNtv has subsequently been widely replicated [35] [36] [37] [38] [39] [40] [41] [42] [43] , with TTNtv accounting for ~15% of DCM cases in the largest series of unselected patients 41, 43 (although much more rarely identified in paediatric DCM 36, 44 ). TTN sequencing has been adopted routinely in diagnostic laboratories, markedly increasing the yield and, therefore, the utility of genetic testing in DCM for confirmatory and familial screening.
In addition to autosomal dominant DCM, TTN variants have been associated with other phenotypes, including peripartum cardiomyopathy 24, 37, 45 and a penetrant cardiomyopathy with predominant LV noncompaction and impairment but marked hypertrophy in some family members 46 . TTN variants have also been implicated in a range of skeletal myopathies 34, [47] [48] [49] [50] [51] , some of which (typically recessive forms) are also characterized by cardiac abnormalities (reviewed previously 52 ). Relatives of patients with recessive titinopathies, who carry variants in the heterozygous state, can manifest cardiomyopathy 47 , and cardiac evaluation of these individuals should be considered. Although individual rare missense variants have been reported in patients with HCM [53] [54] [55] , some with evidence of altered protein function, rare TTN variants are collectively prevalent in the general population, and we are not aware of published data robustly demonstrating an increased frequency of inherited or de novo variants in HCM or demonstrating familial segregation, which would confirm this disease association.
Many other genes reported to be associated with DCM interact with titin, and some might act by altering TTN biology. For example, variants in the splice repressor RNA-binding protein 20 (encoded by RBM20), which regulates TTN splicing 56 , are strongly associated with DCM, and disease-associated RBM20 variants alter TTN splicing in rodent models and humans 57, 58 , leading to alterations in titin isoform composition and in cardiac physiology 58 . Altered TTN biology has also been implicated in the pathogenesis of, or molecular adaptation to, several cardiac disease states. These modifications include changes in titin isoform composition, phosphorylation status, and other post-translational modifications in ischaemic cardiomyopathy, DCM, and heart failure with preserved ejection fraction. These modifications are beyond the scope of this Review, but have been discussed previously 1, 59 . The remainder of this Review is focused primarily on the role of TTN variants, particularly TTNtv, in DCM.
Titin-truncating variants Molecular mechanisms. The class (or classes) of variants associated with disease can point to the disease mechanism, but the experimental elucidation of mechanism is
Key points
• Titin-truncating variants (TTNtv) are strongly associated with dilated cardiomyopathy (DCM), but are also prevalent in the general population • TTNtv identified through genetic testing of patients with confirmed DCM might be clinically actionable and informative for the management of probands and their families • The relevance of TTNtv identified through sequencing for other indications is not well defined; such variants can be associated with increased risk of DCM, but in aggregate are not highly penetrant • Haploinsufficiency caused by TTNtv does not clearly explain all the associated molecular and physiological consequences, suggesting that other mechanisms also contribute to disease pathogenesis • Important genetic and environmental determinants of TTNtv penetrance and expressivity remain to be identified far from trivial 60, 61 and illustrate this challenge. Haploinsufficiency is now generally accepted to be the molecular mechanism for this variant class; however, agreement on this point was reached only after decades of debate about loss-of-function versus poison-peptide effects 62, 63 . The analogies with TTNtv are clear.
TTNtv associated with DCM most commonly occur in the A-band, although they can be located in constitutively incorporated exons anywhere in the titin molecule from the Z-disc to the A-band 19 . In our early imaging genetic association studies, we observed a position-related effect of TTNtv on cardiac function, with worse function linked to more distal variants 38 . This finding suggested that haploinsufficiency might not be the molecular mechanism for TTNtv, because all variants might be expected to have similar positionindependent effects, and a poison-peptide effect was suggested. However, we were not able to demonstrate the existence of a truncated titin protein isoform in cardiac muscle extracts from patients with TTNtv. In subsequent studies of cardiomyocytes derived from induced pluripotent stem cells (iPSCs) from patients with TTNtv, or created using CRISPR-Cas9 gene-editing technology, strong evidence emerged for a haploinsufficient mechanism, although in one cell line, a truncated titin protein was observed 64 .
In an effort to dissect the precise mechanism by which TTNtv lead to DCM, our group created two mutant rat strains with TTNtv, either in very proximal Z-disc exons or in a distal A-band exon 19 . These were created with the goal of the Z-disc mutant being haploinsufficient because protein should not be created at all, whereas the A-band variant might produce a truncated protein product. As ever, titin biology turned out to be more complicated than expected. Although we unequivocally demonstrated the synthesis of a truncated peptide in the A-band mutant by ribo sequencing (FIG. 2) , the Z-disc mutant unexpectedly generated alternate 5ʹ-terminal peptides that initiated distal to the Z-disc TTNtv 19 . Therefore, both mutants might have generated short titin peptides that could have deleteri ous effects. Nevertheless, both mutant rat strains exhibited nonsense-mediated decay of their respective TTNtv alleles, compensated in small part by upregulation of the wild-type allele, and overall, both had ~40% less sarcomere-spanning titin 19 . On balance, we believe that these data point to loss of function as the domin ant underlying molecular mechanism by which TTNtv cause DCM, although a poison-peptide effect might still have a contributory role and has yet to be conclusively excluded.
Molecular consequences. DCM is characterized by cardiac dilatation and systolic dysfunction, which manifests at the level of isolated cardiac myocytes that contract less rapidly and to a lesser degree than healthy cells 65, 66 . This phenotype is unlike that produced by HCM-causing variants, which result in rapid and vigorous myocyte contraction owing to a sensitized sarcomere. The molecular consequences of TTNtv that lead to the hypocontractile state of the myocyte are beginning to be elucidated (FIG. 3) , and we discuss some of the major advances here.
In studies of the two disparate (Z-disc and A-band) TTNtv in the rat, we demonstrated common metabolic and signalling perturbations showing the positionindependent effects of TTNtv 19 . TTNtv resulted in a shift in cardiac metabolism away from the use of long-chain fatty acids, the preferred substrate of the healthy heart, and an increased reliance on glycolysis. This shift in metabolism occurred in young rats in which cardiac performance was normal 19 . A shift towards glycolytic metabo lism is an established, short-term adaptive response of the heart to any stressor [67] [68] [69] [70] . However, prolonged elevation of glyco lytic intermediates and branched-chain amino acids can lead to activation of serine/threonineprotein kinase mTOR complex 1 (mTORC1) signalling 71, 72 , which in turn activates futile cycles of protein synthesis and inhibits autophagy, which are maladaptive responses 73, 74 . In rats with TTNtv, we showed activation of mTORC1 and phosphorylation of its downstream substrates, which has been documented in cardiac biopsy samples from patients with end-stage DCM 74 . Future studies will be needed to determine whether autophagy is impaired in hearts affected by TTNtv, but if so, restoring normal protein processing might provide an avenue for therapeutic intervention. This res toration might be achieved by inhibiting mTORC1 activation, either directly or indirectly, with existing therapies such as metformin or rapamycin derivatives.
In cardiomyocytes derived from human iPSCs, TTNtv were associated with diminished and disorganized sarco meres, and cells were poorly responsive to adrenergic or growth factor stimulation 64 . At the molecular level, major signalling pathways (involving transforming growth factor-β, vascular endothelial growth factor, and mitogen-activated protein kinases) that are critically important to cardiomyocyte function were inhibited 64 , although the mechanism underlying the general attenuation of signalling was not studied.
Physiological consequences. TTNtv are associated with DCM, but are also seen in the general population and can manifest in many different ways (discussed in detail below). First, we summarize the effects of TTNtv on cardiac physiology.
Several studies of various TTN variants (including TTNtv) in mice have been performed 75, 76 . Some of these data remain preliminary, but overall, TTNtv seem to have very limited, if any, effect on cardiac morphology or function in mice in the absence of a stressor. However, after exposure to pharmacological or haemodynamic stress, mouse hearts with TTNtv dilate and develop systolic dysfunction, which is accompanied by a marked fibrotic Z-disc Nature Reviews | Cardiology 179,650,000 179,600,000 179,550,000 179,500,000 179,450,000 179,400,000 77, 78 . In rats, we found a very mild pheno type of ventricular dilatation and impaired systolic function in aged (>1.5 years) rats, but found no effect in younger animals 19 . In ex vivo studies, hearts with TTNtv had normal, or indeed slightly better, cardiac indices compared with those of controls (perhaps reflecting a compen sated state). However, hearts with TTNtv did not exhibit an appropriate Frank-Starling response to volume loading and quickly became dysfunctional 19 . We note that cardiac titin differs between rodents and humans, with distinct isoform compositions that might lead to differences in penetrance and expressivity of TTNtv between species. Taken together, these data show that TTNtv do not cause overt autosomal dominant cardiomyopathy in rodents, but that rodent hearts with TTNtv are primed to fail when exposed to stressors. We proposed that signalling and metabolic adaptations in TTNtv hearts maintain the heart in a compensated state, but at the expense of being unable to respond to a secondary insult.
The physiological effects of TTNtv have also been studied in cardiomyocytes derived from human iPSCs 64 . These studies showed that TTNtv cause impaired contractility of cardiomyocytes at baseline and in response to stress, which is probably related to direct effects on the sarcomere. In humans, the physiological and pathophysio logical effects of TTNtv have been studied in the general population and in patients with DCM by use of both echocardiography and cardiac MRI 19, 38, [40] [41] [42] [43] 79, 80 . The association between TTNtv and DCM is robust and widely replicated, but not all individuals with TTNtv develop DCM. Moreover, the question remains as to whether DCM associated with TTNtv is pathophysiologically distinct from other forms of DCM. These issues will be discussed later in this Review. In echocardiographic studies, no effect of TTNtv on cardiac physiology was detected in the general population 38 . However, these studies were probably underpowered because echocardiography is semiquantitative and inexact. The findings prompted careful evaluation of cardiac morphology and function in a cohort of healthy individuals (n = 1,409) by use of cardiac MRI combined with 2D studies and 3D machine-learning-based analyses 19 . These investigations showed that TTNtv in constitutive exons lead to a slight increase in the size of the heart, with reduced contractility and mild eccentric remodelling 19 . Therefore, although TTNtv are penetrant in the general population, expressivity is limited.
Clinical interpretation of TTN variants
The identification in 2012 of a robust association between TTNtv and DCM had a major effect on the clinical investi gation of patients with cardiomyopathy. The percentage of patients with DCM that could be explained genetically was previously very low (~10% 36 ). Moreover, genetic testing had limited utility and was recommended only in specific circumstances, such as in the presence of concurrent conduction disease suggesting a lamino pathy [81] [82] [83] . We now know that TTNtv account for ~15% of all DCM cases identified in the clinic, and up to ~25% of severe, end-stage, or clearly familial cases of DCM, increasing the utility of diagnostic sequencing 20, 84 (BOX 2). Nevertheless, for genetic testing to be of value, it is necessary to be able to ascribe causality confidently to a specific genetic vari ant in an individual patient. Although TTNtv are more prevalent in individuals with DCM than in control popu lations, the burden of TTNtv in both unselected reference samples 38, 85 and demonstrably healthy controls 19, 38 is substantial. If healthy individuals frequently carry TTNtv, how confident can we be that a variant found in a patient with DCM is disease-causing and not just an innocent bystander?
Modelling the genetic architecture of inherited diseases. In addressing this question, the challenges and limitations that are generally applicable to many Mendelian diseases of variable penetrance and expressivity should be acknowledged. First, DCM is a categorical label, implying binary presence or absence of a disease state. However, a diagnosis of DCM is based on the assessment of continuous parameters (volumes and contractility) with superimposed diagnostic thresholds, and an underlying cardiomyopathic process can also lie on a continuum (analogous with blood pressure effects). Second, much of our understanding of cardiomyopathies (and other inherited diseases) and associated terminology arises from a pure dominant Mendelian disease model, in which the presence or absence of a single allele determines the presence or absence of disease, and in which the allele can be understood as causal. This all-or-nothing eventuality is rare and conceptually contrasts with the understanding of common diseases such as coronary artery disease and An inferred-complete metatranscript comprising 363 exons can be used as a reference for convenience to describe most features. Biologically, two transcripts predominate in the heart -a long and compliant N2BA isoform, and a shorter and stiffer N2B isoform that contains fewer I-band spring elements. A third isoform, Novex-3, utilizes an alternative 3ʹ exon (exon 46) that cannot be represented in the metatranscript and is expressed in the heart at lower levels. Novex-3 is not thought to span the sarcomere, and its functions are not well characterized. Other low-abundance cardiac transcripts, fetal isoforms, and skeletal muscle isoforms are transcribed from the same gene, but are not shown here. ANKRD, ankyrin repeat domain-containing protein; BIN1, MYC box-dependentinteracting protein 1; BRAF, serine/threonine-protein kinase BRAF; FHL, four and a half LIM domains protein; FN3, fibronectin type III; HSPB1, heat shock protein-β1; MARP, muscle ankyrin repeat protein; mHSP90, methylated heat shock protein HSP 90; MYBPC, myosin-binding protein C; NBR1, next to BRCA1 gene 1 protein; PKA, cAMPdependent protein kinase; PKG, cGMP-dependent protein kinase; S100A1, protein S100A1; sANK1, small ankyrin 1 (alternatively spliced variant of ankyrin 1); SMYD2, N-lysine methyltransferase SMYD2; TRIM55, tripartite motif-containing protein 55; TRIM63, E3 ubiquitin-protein ligase TRIM63. Part b data from REF. ◀ hypertension, in which many variants (each with a small effect) contribute to the phenotype, usually without any individual variant that can be meaningfully considered causal, and in which all variants are risk factors.
The pure (but rarely realized) dominant Mendelian model of disease can be readily extended to consider additional variants that either contribute independently to the disease process in an additive fashion, or that modify the effect of a primary deleterious allele through an interaction and, therefore, contribute to the overall risk. However, if the disease process is influenced by multiple contributing factors, when can an individual variant be described as causal? How much of the disease risk should be attributable to an individual variant to be able to label it as the primary cause?
Causative variant or risk allele? This issue can be addressed with well-established, mathematically-based epidemiological measures. The attributable risk percent among exposed (ARP) provides an estimate of the proportion of the risk in an exposed population that can be attributed to the exposure. In our context, this corresponds to the proportion of the risk of cardiomyopathy in mutation carriers that can be attributed to that particular mutation (derivation and interpretation reviewed previously 41 ; Supplementary information S1 (box)). Considering patients with DCM and any TTNtv, the ARP is estimated at 91%, confirming -on an epidemiological basis -that TTNtv are the principal determinant of DCM in this cohort.
The ARP can also be conveniently expressed as a decimal fraction, dubbed the aetiological fraction. When the goal is to determine whether an individual rare variant is likely to be 'causative' , this can be interpreted as the proportion of variant-carrying probands in whom the variant was causal; as the proportion of variants (found in affected individuals) that were penetrant; or as the probability that an individual rare variant, found in a proband, was responsible for the disease. Consensus guidelines for vari ant interpretation in genetic testing suggest that a vari ant can be considered 'likely pathogenic' if the probability that it is causative is >0. 90 Conceptually, two possible explanations exist for the observation that TTNtv do not completely explain the risk of DCM, even among carriers of TTNtv. First, two distinct populations of variants could be present, some with disease-causing potential and others that are benign with no role in the disease. In other words, the variants that are prevalent in the general population are quali tatively different from the disease-causing variants in patients with DCM, and a proportion of these patients will carry a benign TTNtv by chance. Alternatively, all TTNtv might have disease-causing potential, but display vari able penetrance and expressivity because of other (genetic, environmental, or stochastic) factors that account for the residual risk. The data suggest that the truth lies in a combination of these explanations, which we and others suggest is true for many Mendelian diseases.
Characterizing background variation in the general population. Of the variants observed in healthy controls, 14% of TTNtv are found in a single exon: exon 48 (REF. 38 ) (we use the exon numbering adopted by the Locus Reference Genomic reference transcripts, in which all possible exons are numbered 1-364 according to genomic location, irrespective of isoform inclusion). Exon 48 is an alternative 3ʹ (C-terminal) exon used only by the Novex-3 transcript that is expressed at low levels in the heart and does not span the sarcomere. Variants in this exon are equally common in patients with DCM and in control individuals 19, 38 . A further 12% of variants are found in other exons with minimal cardiac expression, and another 20% are found in exons that are expressed in the heart but are incorporated only into the longer isoforms 38 . In total, ~46% of the variants found in healthy controls are located in exons that are either not incorporated into the main cardiac isoforms at all or are utilized only in the long N2BA isoform, such that a fully functional N2B isoform can still be transcribed and translated from the variant allele 19, 38 . A further number of the TTNtv observed in controls are individually fairly common, or at least insufficiently rare to be penetrant causes of DCM (general population allele frequency >1 × 10 −4 ) 19 . Some of these variants are found in the nonconstitutive exons described above, and the remainder are typically variants predicted to disrupt splicing. Although variants that alter canonical splice donor and/or acceptor sequences are conventionally considered to be truncating, such effects can be rescued by alternative splice sites nearby or can result in exon-skipping that might be tolerated if the resultant transcript preserves the reading frame.
Clinical interpretation of TTNtv in DCM probands.
If we exclude categories of variants that are prevalent in healthy individuals and consider only rare TTNtv in exons that are constitutively expressed in the heart, the aetiological fraction for TTNtv in DCM probands rises to 0.97 (REF. 19 ). The clear majority of disease risk can be attributed to these variants. We estimate that the prob ability that such a variant is causal of the observed disease is 0.97, and that a TTNtv in a constitutive exon found in a patient with DCM is, therefore, an actionable finding. We would, for example, consider using the variant for predictive testing in family members, reassuring and discharging from surveillance in the cardiology clinic individuals found to be genotype negative.
Interpretation of TTNtv in healthy individuals.
Although such variants are actionable when found in a patient with known disease, this information does not indicate what proportion of family members, or unrelated individuals, who are found to have such a variant will go on to develop disease. Relatives of patients with DCM have been investigated in several studies 23, 40, 42, 79 . Although the total number of individuals and distinct DNA variants studied remains small, the picture is one of age-related penetrance: 29-65% by the age of 50 years and 83-100% by the age of 70 years (FIG. 4) .
The penetrance looks rather different when TTNtv are examined in the general population. Again, considering only TTNtv in exons constitutively expressed in the heart, the prevalence of rare variants in the general population is ~1:250 (0.4%) 19 . If the upper estimate of the population prevalence of DCM of 1:250 is used 21 and if ~13% of cases are assumed to be associated with TTNtv 19 , this yields an estimated penetrance of 0.12 (0.093-0.150) in the general population (calculated using a method described previously 87, 88 ). If the true prevalence of DCM is lower than 0.4%, then even lower penetrance for these variants is implied.
Therefore, most individuals with TTNtv will not develop overt DCM, but the variants are not necessarily phenotypically silent. Indeed, we have shown that individuals in the general population with TTNtv have slightly larger hearts, with subnormal contraction and early features of eccentric remodelling 19 . Whether the metabolic and signalling phenotype observed in model organisms 19 is recapitulated in humans with TTNtv but not DCM, and whether TTNtv confer a substantially increased risk of heart failure as suggested by animal physiology 19 and their association with peripartum cardiomyopathy 24 , remains to be determined. Analysis of the regional distribution of TTNtv in patients and controls reveals further subtleties for their clinical interpretation. Missense variants that result in single amino acid substitutions can have very different effects depending on their molecular location -one variant might disrupt a phosphorylation site resulting in disinhibition, whereas a variant at a catalytic site might ablate enzyme activity. By contrast, protein-truncating variants are generally considered equal (with some caveats) 89, 90 . Cells have mechanisms to identify and remove truncating transcripts and their protein products (for example, nonsense-mediated decay and proteasomal degradation). Therefore, in most cases, the truncated peptide is not present at a detectable level in the cell, and the molecular consequence of the variant, if any, is simple deficiency 91 . Classically, the location of the truncating variant should not matter -all truncations should have the same downstream consequence, as we found in rat models with TTNtv at opposite ends of TTN 19 . We have already seen that TTNtv in certain regions of the protein are not associated with disease, but this observation can be explained by tissue-specific expression patterns of the various isoforms. Variants must affect cardiac isoforms to cause cardiac disease, but even so, not all TTNtv are created equal. In early studies of TTNtv in DCM, variants in the A-band were highlighted as particularly important 23 . Subsequently, we noted that A-band exons are all constitutively expressed in the heart and that other constitutive exons are also robustly associated with disease 19, 38 . For example, exon 49, encoding the N2B element that differentiates cardiac and skeletal titin isoforms, is located in the I-band but has an odds ratio of 34 (95% CI , suggesting that all constitutive exons are equally important. However, a positional effect remains even among constitutively expressed exons. In one study, TTNtv located more distally (near the A-band end) were proposed to lead to a more-severe phenotype than those located more proximally (near the I-band) 38 . However, the number of distinct variants studied was small, and this finding has not been replicated. In the largest meta-analysis conducted so far, the odds ratio for DCM was higher for variants in the distal I-band and the A-band, and lower for TTNtv at the Z-disc or M-line 19 . This finding remains poorly understood. Although transcripts containing variants in the last two exons might be expected to escape nonsensemediated decay 90, 92 , this exception does not account for the differences in odds ratio observed. Alternative 5ʹ start sites have been proposed as an explanation -perhaps We studied a heterozygous A-band titin-truncating variant (TTNtv) rat model, specifically a Fischer (F)344-Brown Norway (BN) rat F1 genetic cross, in which the truncating allele is tagged by F344 strain-specific single nucleotide polymorphisms (SNPs), while the wild-type allele carries BN-specific alleles. At heterozygous SNP sites, we use the ratio of sequencing reads arising from each allele (allele balance) to infer levels of transcription and translation. a | RNA sequencing (RNA-seq) data (white points) contain reads from F344 alleles, but the truncating allele (carrying F344 SNPs) represents only 20-30% of reads, suggesting degradation of the mRNA, upregulation of the wild-type allele, or both. In ribosequencing (Ribo-seq) data (purple points), we again see reads from the mutant allele up to the location of the truncating variant (purple line), after which the transcript is dissociated from the ribosome and no longer translated. This demonstrates that the stop codon is active and terminates translation, but that the truncating transcript is present and translated up to that point. b | Titin protein synthesized after the TTNtv premature stop codon is exclusively generated from the intact BN allele. In box plots, boxes show medians within the 25th to 75th percentile, and whiskers show the 10th to 90th percentile. Allele frequencies in both RNA-seq and Ribo-seq data were <50%, indicative of nonsense-mediated mRNA decay. , might be expressed in full and rescue the situation. We consider this explanation unlikely. Although such start sites exist and are active in humans 19 , the resultant transcripts would not be expected to contain the necessary motifs to incorpor ate into the Z-disc, and the protein would be unlikely to span the sarcomere. Moreover, TTNtv immediately upstream of the Cronos start site, which might be rescued by this mechanism if active, are associated with DCM with an odds ratio similar to that of A-band TTNtv 19 . In our opinion, the mechanism underlying regionality, even within constitutive exons, remains to be determined. One explanation could be that the truncated peptide product is important, with pathogenicity at least partly attributable to a poison-peptide effect.
Nontruncating variants. In this Review, we focus on the role of TTNtv in the heart, but whether other classes of variation in TTN predispose to disease is also worth considering. The first report of an association between TTN variants and DCM included two families, one of which carried a TTNtv, and the other, a missense variant 31 . The missense variant segregated with disease, and stem-cellderived cardiomyocytes genetically engineered to carry the variant were later shown to develop a phenotype consistent with other DCM-causing mutations 64 . Another missense variant has been shown to segregate with a cardiomyopathy characterized by LV noncompaction and impaired function, but with marked hypertrophy in some of the affected individuals 46 . Functional studies suggest partial protein unfolding, domain destabilization, and impaired binding to the titin ligand telethonin to be associated with the variant, providing strong evidence of causality 46 . However, rare missense variants in TTN are extremely prevalent, and their prevalence in patients with DCM is indistinguishable from that in the general population. Other than a few specific variants that have been statistically implicated in DCM through linkage studies in large families and shown to alter protein function in vitro or in vivo, the majority of missense variants in TTN remain uninterpretable, whether identified in the context of genetic testing for DCM or as an incidental finding in other sequencing.
Structural variants, including copy number variants that alter dosage of the TTN gene, are not well characterized. Targeted high-throughput sequencing has limited accuracy for the detection of such variants, and largescale systematic analyses are lacking. In the seminal case series reported by Herman and colleagues, one patient with DCM carried a copy number variant leading to a partial internal duplication that would be expected to disrupt the protein structure 23 . However, larger copy number changes that might affect gene dosage -for example, the 2q31.2q32.3 deletion syndrome [94] [95] [96] [97] [98] [99] -are not typically associated with cardiomyopathy (although cardiac evaluation might have been variable and not necessarily performed in late adulthood).
Summary of clinical interpretation.
Many rare TTNtv found in exons that are constitutively expressed in the heart are clinically actionable when found in a patient with DCM (FIG. 5) . The probability that such a variant is causative in the observed disease is >0.97, justifying a guideline-based classification 86 of 'likely pathogenic' and consideration of molecular cascade screening with suitable genetic counselling. The probability that a relative who does not carry the familial TTNtv will nevertheless develop DCM approaches the background level of risk in the general population, and we believe that such individuals do not routinely require long-term follow-up.
By contrast, the penetrance of TTNtv is not fully characterized, and data are lacking to reconcile the apparently high penetrance (albeit strongly age-related) in relatives of patients with DCM with lower penetrance in the general population. The proportion of TTNtvpositive individuals who are related to patients with DCM who will eventually manifest disease cannot yet be determined. However, our practice is to maintain surveillance of these individuals, for example, clinical review and imaging every 2-3 years. Variants identified incidentally in the general population, in individ uals with no family history of DCM, might prove to be risk factors for heart muscle disease, but the risk is not yet well characterized. Our understanding of factors that determine penetrance is limited but evolving, and we anticipate that both genetic and environmental modifying factors will soon be identified.
TTNtv and precision medicine
The identification of TTNtv as a major cause of DCM has had an important effect on the clinical management of patients with this condition, doubling the proportion of genetic tests that yield an informative result (that is, identify the causative variant), which, in turn, enables cascade screening. A definitive molecular genetic result in a proband with DCM will free ~50% of their relatives from the burden of long-term cardiological surveillance -including electrocardiography and echocardiography or cardiac MRI every few years, at substantial cost to both individuals and the health system. Although the study of TTN-related cardiomyopathy is still at an early stage, the available data suggest that molecular genetics has the potential to affect the management of patients with DCM directly. In this era of precision medicine, we can hope that the identification of a TTNtv will inform prognosis and treatment stratification, in addition to the benefits of molecular cascade testing to the patient's family. To date, the power of case series to characterize genetic associations definitively with phenotype or clinical outcome has been limited. In the seminal paper that defined the importance of TTN in DCM, the investigators reported "no significant differences between subjects with and those without TTN truncating mutations with respect to the age at diagnosis, left ventricular end-diastolic dimensions, ejection fraction, or rates of cardiac transplantation, implantation of a left ventricular assist device, and death from cardiac causes", but also noted that "men with TTN [truncating] mutations had adverse events at significantly earlier ages than did women (P = 4 × 10 −5 )" (REF. 23 ). Case series have reported the highest prevalence of TTNtv among patients with severe disease or among those evaluated for cardiac transplantation 23, 38 , suggesting that the identification of a TTNtv might inform prognosis.
In our own early series of 319 patients (42 with TTNtv) with quantitative cardiac MRI parameters, we found that ambulatory patients with DCM and TTNtv had only marginal reductions in wall thickness ( unadjusted indexed lateral wall thickness 2.77 ± 0.7 mm versus 3.13 ± 0.7 mm; P = 0.003) and contractility indices (LV ejection fraction (LVEF) 33.3 ± 13% versus 37.5 ± 12%; P = 0.047 in unadjusted analysis, P = 0.006 in analysis adjusted for covariates) compared with those without TTNtv 38 . Preliminary analyses based on a subset of the cohort suggested an increase in history of ventricular tachycardia (VT) by the time of recruitment, but the sample size was modest (of 111 patients with ventricular arrhythmia data, VT was observed in 9 of the 14 patients (64%) with TTNtv and 20 of the 97 individuals (21%) without TTNtv) 38 .
An extension of this work included a comprehensive analysis of early arrhythmia history in a larger cohort of ambulatory patients with DCM (n = 572; 56 with TTNtv; mean LVEF 39 ± 12.6%) 80 . The association between TTNtv and arrhythmia proved robust. Patients with TTNtv had a threefold increased risk of a hospital or primary care record of atrial fibrillation or VT by the time of recruitment after adjusting for conventional arrhythmic risk factors (adjusted OR 2.9, 95% CI 1.5-5.8, P = 0.002; absolute risk increase 13%). Arrhythmias were docu mented in 196 patients (34%): 139 (24%) with atrial fibrillation, 69 (12%) with nonsustained VT, and 11 (2%) with sustained VT. Overall, 22 patients had more than one type of arrhythmia. TTNtv were observed in 26 patients (13.3%) with a history of arrhythmia and in 30 patients (8%) without recorded arrhythmia. Conversely, an arrhythmia was documented in 26 patients (46%) with TTNtv compared with 170 patients (33%) without TTNtv (P = 0.05) 80 . In a study conducted in the Netherlands, probands with DCM and TTNtv (n = 45), LMNA variants (the gene encoding prelamin-A/C; n = 28), or variants in neither gene (n = 60), and their relatives were evaluated 79 . During the study period (median 2.5 years), TTNtv were associated with a milder clinical course than were LMNA variants, which are known to be associated with arrhythmia, conduction disease, and aggressive disease 100, 101 . In addition, carriers of TTNtv were compared with patients with DCM who had neither LMNA nor TTN variants. The proportion of TTNtv carriers with an LVEF <35% at diagnosis was lower than that among Nature Reviews | Cardiology Herman et al. 23 Akinrinade et al. 40 Jansweijer et al. 79 Franaszczyk et al.
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Figure 4 | Age-related penetrance of titin-truncating variants. Titin-truncating variants (TTNtv) identified in probands with dilated cardiomyopathy (DCM) seem to be penetrant in family members, albeit with a strong age-dependent effect. Unbiased estimates of penetrance (the proportion of variant carriers who manifest the disease) are difficult to obtain 87 , but population approaches suggest a penetrance of around 0.1. The penetrance of TTNtv in a familial context has been investigated in four studies examining TTNtv-carrying relatives of patients with TTNtv-associated DCM. Herman et al. 23 studied 32 variant carriers aged >40 years and reported >95% of these carriers as being affected by DCM. Akinrinade et al. 40 , Franaszczyk et al. 42 , and Jansweijer et al. 79 reported penetrance by decade, yielding a picture of strongly age-related penetrance, but also showing that most variants are ultimately penetrant if followed up into older age.
those with DCM and no identified variants, and TTNtv were associ ated with a trend towards a more favourable disease course (compo site outcome of ventri cular arrhythmia, transplantation, LV assist device implantation, and all-cause mortality) 79 . The rate of VT was nominally higher in those with TTNtv than in those without a vari ant in either gene (35% versus 11%, P = 0.04; HR 3.1, P = 0.06), in accordance with our own findings, although other arrhythmic end points did not differ between the groups 79 . In another study, evaluation of 72 probands with DCM (17 with TTNtv) revealed no difference in the incidence of adverse cardiac events between carriers of TTNtv and noncarriers (mean follow-up 63 months) 42 , although the investigators did report a higher penetrance and poorer outcomes in male carriers of TTNtv than in female carriers 42 . An extension of our work published in 2017 explored clinical outcomes in a larger ambulant population with DCM (716 patients, 83 with TTNtv, 604 with follow-up data; median follow-up 3.9 years) alongside an expanded analysis of phenotype at recruitment 43 . The increased propensity to arrhythmia early in the disease course did not translate to a significant difference in prognosis over the medium-term for patients with DCM and TTNtv (HR 0.92, 95% CI 0.45-1.87, P = 0.82 for a primary composite end point comprising sustained VT or fibrillation, appropriate implantable cardioverter-defibrillator shock, aborted sudden cardiac death, heart transplantation, LV assist device implantation, and hospitalization for heart failure), although the overall event rate (12.9%) was relatively low compared with registry data. TTNtv were also associated with thinner LV walls (mean maximum LV wall thickness 8.8 ± 1.8 mm versus 10 ± 2.2 mm; P < 0.001) and lower LV mass (5.1 g/m 2 reduction; P = 0.03 in adjusted analysis) in the absence of evidence of significant differences in LV dilatation. Although the magnitude of the difference was small and not clinically informative, such a blunted hypertrophic response could be consistent with altered mTORC1 signalling, which can modulate cardiac hypertrophy, as discussed above, but a mechanistic link remains to be established.
With the exception of the reported link between TTNtv and early-onset arrhythmia 38, 80 , when taken together, the published data on genotype-phenotype associations in DCM associated with TTN variants do not yet provide evidence of a markedly distinct phenotype or altered clinical course. Whether TTNtv predict outcome in the longer-term or are informative in a subgroup of patients at higher risk remains to be established. By contrast, cardiomyopathy associated with LMNA variants is associated with poor prognosis.
Importantly, TTNtv are reported to be associated with a favourable response to treatment 79 . This observation is concordant with our findings in a cohort of 70 patients with end-stage DCM referred for LV assist device implantation 102 , and with those in a group of 128 patients with DCM from Canada, among whom those with TTNtv were no less likely to respond to medical therapy than those without such variants 103 . Together, these findings update the conventional wisdom that irreversible genetic aetiology correlates with irreversible disease 104 , suggesting instead that TTNtv do not preclude recovery and should not be a barrier to advanced therapies.
Evidence is accumulating that TTNtv are also found in association with cardiomyopathies traditionally considered as secondary, such as those related to pregnancy 24 or cardiotoxic chemotherapy 105 . The implication is that, in a proportion of patients, TTNtv might be acting in concert with other factors, such that treatment of the exacerbating factor might be expected to lead to substantial recovery.
The potential for TTN genotype to have a role in other forms of precision therapy, beyond risk stratification, remains speculative. The use of therapies based on genetic engineering is foreseeable in the long term, but the appropriate strategy -for example, gene replacement therapy for haploinsufficiency, allele-specific silencing if the variant is a dominant negative, or direct gene editing to correct or ameliorate the molecular defect -will depend on an improved understanding of the molecular mechanisms involved. Exon-skipping induced by antisense oligonucleotides to restore the reading frame has shown efficacy in experimental models, including mice and cardiomyocytes derived from human iPSCs 106 . An equivalent therapeutic strategy has received FDA approval for human use in Duchenne muscular dystrophy 107 . Figure 5 | Clinical interpretation of TTNtv in a patient with DCM. A proposed systematic approach to the interpretation of titin-truncating variants (TTNtv). Variants should be sufficiently rare to be a plausible disease allele 86, 88 . Truncating variants in exon 48, exons that are not expressed in the heart, or exons that are not constitutively expressed in the heart have not been shown to be associated with dilated cardiomyopathy (DCM). Variants in cardiac constitutive exons are associated with DCM, but the strength of the association differs for various protein regions. When found in a patient with DCM, variants in the A-band, distal I-band, or exon 49 (encoding the N2B unique element) have a high probability (>0.95) of being causal and are clinically actionable. Variants in other constitutive exons might require additional evidence for confident interpretation. TTNtv identified as secondary findings, such as during sequencing for other indications, cannot be assumed to confer the same disease risk as TTNtv identified in the context of disease and are unlikely to be clinically actionable. The presence of a metabolic phenotype in rat models, with accompanying changes in signalling pathways including mTOR, suggests other strategies for potential evaluation, such as mTOR pathway modulation with metformin or 'rapalogues' (rapamycin analogues). Alternatively, the study of genetic or environ mental modi fiers of TTNtv expressivity and penetrance might reveal secondary pathways that are amenable to therapeutic modulation.
Conclusions
Titin is central to sarcomere structure and function, and genetic variation can lead to altered cardiac function and heart disease. However, studies to dissect the molecular mechanisms and consequences of titin variation have highlighted the subtlety and diversity of the role of this protein. Far from being simply a large, passive structural molecule, titin is complex, with varied structural, sensing, and signalling functions.
Inevitably, a gene the size of TTN will undergo frequent mutation. Titin function seems to be maintained in the face of much genetic variation, harbouring very many rare missense and truncating variants in the general population. Although heterozygous TTNtv are the most common genetic predisposition to DCM, most individuals who carry such variants do not have overt disease. However, TTNtv in the general population are not phenotypically silent -a picture is emerging of subclinical cardiac changes that might predispose to heart failure under conditions of physiological stress or toxic insult or in the context of a susceptible genetic background.
In patients who present with DCM, the finding of TTNtv enables molecular cascade screening of family members that can free these individuals from a lifetime of surveillance in the cardiology clinic. Although the importance of TTNtv in DCM was not appreciated fully until 2012, in the past 5 years, TTN sequencing has already transitioned into clinical care, with the potential to influence patient stratification. Whether a molecular diagnosis will routinely enable patient selection for targeted therapeutic intervention remains to be seen, but the signs are promising, and much work is in progress.
